Approval · Notice of Compliance 94 · 2004
APRESOLINE: Notice of Compliance 94
Issued March 5, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 94
- Date
- March 5, 2004
- Company
- Sterimax Inc.Oakville, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Antihypertensive agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APRESOLINE | 00005525 | Cancelled Post Market |
| APRESOLINE | 00005533 | Cancelled Post Market |
| APRESOLINE | 00005541 | Cancelled Post Market |
| APRESOLINE | 00723754 | Dormant |
Medicinal ingredients
- HYDRALAZINE HCL 10 MG per TAB
- HYDRALAZINE HCL 25 MG per TAB
- HYDRALAZINE HCL 50 MG per TAB
- HYDRALAZINE HCL 20 MG per AMP